303 results on '"Ponziani, F.R."'
Search Results
2. Metástasis esplénica y pulmonar de carcinoma hepatocelular detectado en13N-NH3 PET/TC
3. Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: A prospective pilot study
4. Prophylaxis of HBV-recurrence after liver transplantation in patients with HCC: Risk of HCC recurrence from a large, multicentre retrospective study from Italy
5. Longer transplant-free and liver-related event-free survival in obeticholic acid-treated patients with primary biliary cholangitis compared to external controls from two large real-world cohorts
6. FVIII/PC and ADAMTS13/VWF ratio to predict liver-related events and mortality in patients with ACLD
7. Long-term results from the Italian real-world experience on obeticholic acid treatment in primary biliary cholangitis: The RECAPITULATE study
8. Prevalence and predictiors of porto-sinusoidal vascular disorder in patients with constantly elevated gamma-glutamyl transferase levels: A multicenter Italian study
9. T.03.10 HIGH RATE OF LATE REFERRAL AND DIAGNOSIS OF LIVER CIRRHOSIS DURING A FOUR-YEAR PERIOD IN A SECOND LEVEL MEDICAL CENTER: THE EXPERIENCE OF FONDAZIONE POLICLINICO GEMELLI
10. Prediction of response to obeticholic acid in primary biliary cholangitis: Development and validation of the OCA response score (ORS)
11. Management of Hepatitis C Virus Infection Recurrence After Liver Transplantation: An Overview
12. Hepatocellular carcinoma with portal vein tumor thrombus: a single-center retrospective analysis
13. Can AtezoBev be a safe and effective option for treating hepatocellular carcinoma in patients with Child-Pugh B cirrhosis? A retrospective multicenter real-world study
14. Safety and efficacy of direct oral anticoagulants in cirrhotic and non-cirrhotic patients with splanchnic vein thrombosis: preliminary results from sapient study
15. OC-11Development of NAFLD/NASH multidisciplinary board: MetaLiverCat experience
16. Hepatocellular liver injury in hospitalized patients affected by COVID-19: Different factors at different time points
17. Increased Faecalibacterium abundance is associated with clinical improvement in patients receiving rifaximin treatment
18. MetaLiverCat: the NAFLD/NASH multidisciplinary board at Fondazione Policlinico Gemelli IRCCS
19. Prevalence and pattern of atherosclerotic changes in primary biliary cholangitis and in non-alcoholic fatty liver disease
20. Clinical impact of comorbidities in an Italian NAFLD cohort
21. Prognostic role of HepPar1 positive circulating microparticles after hepatectomy for hepatocellular carcinoma
22. P.09.22 MARKERS OF HEPATOCELLULAR CARCINOMA OCCURRENCE AFTER TREATMENT WITH DIRECT ACTING ANTIVIRALS
23. P.09.10 CIRRHOTIC PATIENTS WITH MINIMAL HEPATIC ENCEPHALOPATHY PRESENT INCREASED CEREBRAL VASCULAR RESISTANCE, WHICH REMAINS UNCHANGED AFTER MEDICAL TREATMENT
24. P.09.23 COMMON CLINICAL COMORBIDITIES IN AN ITALIAN NAFLD COHORT
25. Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with HCV-related cirrhosis
26. P.10.7: The GUT Liver Axis after Liver Transplantation: Modification of Intestinal Permeability and Correlation with Infectious Complications and Patients Prognosis
27. P.09.4: Effectiveness of HCV Antiviral Treatment in Patients with Cirrhosis or Advanced Fibrosis and end-Stage Kidney Disease on Dialysis
28. Effectiveness of HCV antiviral treatment in patients with cirrhosis or advanced fibrosis and end-stage kidney disease on dialysis
29. Daclatasvir/sofosbuvir and ribavirin 800mg flat dose is highly efficacy and safe in genotype 3 compensated and decompensated cirrhotic patients: The CLEO experience
30. Leaky gut does not affect the risk of infectious complications and survival in liver transplant recipients: comparison with cirrhotic patients and healthy individuals
31. The gut microbiome of lean patients with non-alcoholic steatohepatitis: comparison with overweight/obese counterparts and healthy subjects, correlation with dietary intake and liver histology
32. The gut microbiota of cirrhotic patients with poor nutritional status: Preliminary evidences
33. Accuracy of intestinal permeability in predicting the development of complications in patients with liver cirrhosis
34. Increased Faecalibacteriumabundance is associated with clinical improvement in patients receiving rifaximin treatment
35. SERUM ALPHA-FETOPROTEIN MODIFICATION (DELTA-AFP) IS A HIGHLY SPECIFIC TOOL TO SUSPECT HCC RECURRENCE AFTER LIVER TRANSPLANTATION
36. First steps towards understanding the dynamic evolution of gut microbiota in different stages of liver disease
37. Daclatasvir/sofosbuvir and ribavirin 800 mg flat dose is highly efficacy and safe in genotype 3 compensated and decompensated cirrhotic patients: The CLEO experience
38. FRI-497 - Leaky gut does not affect the risk of infectious complications and survival in liver transplant recipients: comparison with cirrhotic patients and healthy individuals
39. THU-380 - The gut microbiome of lean patients with non-alcoholic steatohepatitis: comparison with overweight/obese counterparts and healthy subjects, correlation with dietary intake and liver histology
40. P885 RECIPIENT AND DONOR GENDER MATCH PREDICTS THE OUTCOME OF ANTIVIRAL THERAPY FOR RECURRENT HEPATITIS C
41. P.16.15 FEASIBILITY AND ACCURACY OF ELASTPQ® SHEAR WAVE ELASTOGRAPHY TECHNIQUE AND DOPPLER INDICES IN THE NON-INVASIVE ASSESSEMENT OF LIVER FIBROSIS: A PRELIMINARY EXPERIENCE
42. The impact of IL-28B polymorphism and diabetes on SVR after antiviral therapy (AT) for post-liver transplant (LT) HCV recurrence
43. Recipient and donor gender match predicts the outcome of antiviral therapy for recurrent hepatitis C
44. 579 ENDOTHELIAL DYSFUNCTION IN CIRRHOSIS AND ITS RELATIONSHIP WITH PORTAL HYPERTENSION AND LIVER FAILURE
45. 228 THE TRIANGULAR RELATIONSHIP BETWEEN LEAKY-GUT, MICROBIOTA AND SPONTANEOUS BACTERIAL PERITONITIS IN LIVER CIRRHOTIC PATIENTS
46. P.11.13 EPIDEMIOLOGY OF PORTAL AND DEEP VEIN THROMBOSIS IN HOSPITALIZED CIRRHOTIC PATIENTS: A SINGLE CENTER EXPERIENCE
47. P.11.20 CLINICAL OUTCOME OF PARTIAL PORTAL VEIN THROMBOSIS IN CIRRHOTIC PATIENTS: TO OBSERVE OR TO TREAT?
48. P.18.15 CONTRAST-ENHANCED ULTRASOUND EVALUATION OF TUMOR RESPONSE TO ANTI ANGIOGENETIC TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARINOMA
49. P.11.18 GUT MICROBIOTA ALTERATION: THE LINK BETWEEN “LEAKY GUT” AND SPONTANEOUS BACTERIAL PERITONITIS IN LIVER CIRRHOTIC PATIENTS?
50. P.13.7 COMPARISON BETWEEN TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) AND TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION COMBINED WITH PERCUTANEOUS RADIOFREQUENCY ABLATION (TACE-RFA) FOR TREATMENT OF INTERMEDIATE HEPATOCELLULAR CARCINOMA (HCC)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.